Clinical Trial Results TV
November 13, 2010: ROCKET-AF: Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxavan Compared with Warfarin in Patients wi
Dr. Robert Califf, Dr. Manesh Patel, Dr. Ken Mahaffey and Dr. Keith Fox discuss: Stroke
Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in
Patients with Nonvalvular Atrial Fibrillation (ROCKET-AF) at AHA 2010

Kenneth W. Mahaffey, MD
Research Grants: AstraZeneca, Bayer, BI, BMS, Eli Lilly, J&J, Merck, Novartis,
Portola, Regado, Sanofi-Aventis, The Medicines Company
Consulting Fees: AstraZeneca, Bayer, BI, BMS, Eli Lilly, J&J, Merck, Novartis,
Sanofi-Aventis
No stock ownership
http://www.dcri.duke.edu/research/coi.jsp
Keith AA Fox, MB ChB
Research Grants: Bayer, Eli Lilly, J&J, Sanofi-Aventis
Consulting Fees: Bayer, Eli Lilly, J&J, Sanofi-Aventis
No stock ownership

[ Download video ]


Video Statistics
3.75 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 4 total votes.

These statistics are updated nightly. The last update ran on
10-23-2018 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted